Status:
COMPLETED
Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This trial is conducted in Europe. The aim of this trial is to determine the effect of NNC 90-1170 (liraglutide) on glucose and hormonal profiles, fasting gluconeogenesis and insulin secretion in subj...
Eligibility Criteria
Inclusion
- Type 2 diabetes mellitus
- Diet treated and/or subjects in monotherapy with max. 50 % of maximal dose of sulphonylurea (SU). In addition, subjects in treatment with metformin and/or repaglinide could be included
- Body Mass Index (BMI) maximum 35 kg/m\^2
- Fasting plasma glucose 7-15 mmol/l, both inclusive
Exclusion
- Impaired liver function
- Impaired renal function
- Anaemia
- Cardiac disease
- Uncontrolled treated/untreated hypertension
- Recurrent major hypoglycaemia as judged by the Investigator
- Known or suspected allergy to trial product or related products
- Females of child bearing potential who are pregnant, breast-feeding or have intention of becoming pregnant or are not using adequate contraceptive measures
- Current treatment with thiazolidinediones or chronic daily use of insulin (more than 7 days) within three months in the absence of intercurrent illness
- Loss of more than 400 ml blood during the three months prior to study start
- Allergy to paracetamol
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2002
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT01508923
Start Date
May 1 2001
End Date
February 1 2002
Last Update
January 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Århus C, Denmark, 8000